Large Real-World Study Examines Whether GLP-1 Drugs Increase Risk of a Rare Eye Condition | Research

The takeaway

A global real-world cohort study using TriNetX data evaluated whether GLP-1 receptor agonists increase risk of NAION (sudden vision loss) compared to other diabetes drugs.

Real-world NAION risk assessed
GLP-1 RA users compared to other diabetes drug users in large US database

What the researchers found

The study evaluated NAION risk in GLP-1 RA users compared to other antidiabetic drug users and SGLT2i users specifically in a large real-world T2DM population.

Why it matters

NAION causes sudden, often permanent vision loss. With tens of millions taking GLP-1 drugs, even a small increased risk would affect thousands of patients.

How the study worked

Retrospective cohort study using TriNetX US Collaborative Network 2015-2024; adults with T2DM; GLP-1 RA vs other antidiabetic drugs and vs SGLT2i.

What this study cannot tell us

Retrospective observational design; NAION diagnosis in databases may be inconsistent; potential confounding by indication; NAION is rare, limiting statistical precision.

How to read the evidence

Large retrospective cohort study — provides substantial real-world safety data but cannot establish causation.

When this study was published

Published in 2026, addressing an active safety investigation as GLP-1 drug prescribing peaks.

The bigger picture

This study is part of a broader effort to characterize the full safety profile of GLP-1 drugs as their use expands into obesity treatment for otherwise healthy individuals.

Questions still open

If an association exists, is it mediated by rapid weight loss, blood pressure changes, or a direct drug effect?
Should ophthalmologic screening be recommended before starting GLP-1 therapy?

Common questions

What is NAION?

Non-arteritic anterior ischemic optic neuropathy is sudden vision loss caused by reduced blood flow to the optic nerve. It typically affects one eye and can cause permanent vision impairment.

Should I worry about vision loss on GLP-1 drugs?

NAION is very rare regardless of medications. This study helps determine whether GLP-1 drugs slightly increase the already-low risk. If you experience sudden vision changes, contact an eye doctor immediately.

Read the original research

Glucagon-like peptide-1 receptor agonists and the risk of nonarteritic anterior ischemic optic neuropathy: Evidence from a global real-world cohort.

Diabetes & metabolism, 52(2), 101740

View on PubMed ↗Publisher’s paper ↗

Citation

Chen, Jun-Wei; Yu, Frederick Tzu-En; Chen, Hsin-An; Huang, Tzu-Fu; Chen, Harn-Shen; Wu, Tzu-En. (2026). Glucagon-like peptide-1 receptor agonists and the risk of nonarteritic anterior ischemic optic neuropathy: Evidence from a global real-world cohort.. Diabetes & metabolism, 52(2), 101740. https://doi.org/10.1016/j.diabet.2026.101740